Noradrenergic mechanisms for the anticonvulsant effects of desipramine and yohimbine in genetically epilepsy-prone rats: studies with microdialysis.
A large body of evidence suggests that the seizure-prone state of genetically epilepsy-prone rats (GEPRs) results, in part, from deficits in central nervous system noradrenergic function. In order to link the synaptic concentration of norepinephrine (NE) to seizure behavior, we evaluated the effects of both desipramine and yohimbine on convulsions and on extracellular NE and serotonin (5-HT) concentrations in the thalamus of severe seizure GEPRs (GEPR-9s). Under anesthesia, guide cannulae were stereotaxically placed over thalami. After recovery from surgery, dialysis probes were inserted and the animals were placed individually into a plexiglass chamber where they were allowed to move about freely. Artificial CSF was perfused and samples were collected for analysis on HPLC with electrochemical detection. Either desipramine (10 and 20 mg/kg) or yohimbine (10 mg/kg) was administered i.p. after a stable baseline of NE or 5-HT was established. Significant increases in the extracellular NE concentration were seen after injection of both drugs. Temporal linkage exists between the maximum NE increase and the maximum decrease in audiogenic response score (ARS) for these two agents. No significant increases in the extracellular 5-HT concentration occurred after administration of either desipramine or yohimbine at a dose of 10 mg/kg. We conclude that these two drugs are effective anticonvulsants in GEPRs at least partially because they enhance noradrenergic transmission.
Yan
Q S
QS
Department of Basic Sciences, University of Illinois College of Medicine, Peoria 61656.
Jobe
P C
PC
Dailey
J W
JW
D000818:Animals; D000927:Anticonvulsants / Q000494:pharmacology*; D003891:Desipramine / Q000494:pharmacology*; D003956:Dialysis; D004198:Disease Susceptibility; D004827:Epilepsy / Q000235:genetics / Q000503:physiopathology*; D005260:Female; D008297:Male; D008846:Micromanipulation; D009638:Norepinephrine / Q000502:physiology*; D051381:Rats; D012701:Serotonin / Q000378:metabolism; D013569:Synapses / Q000502:physiology; D013788:Thalamus / Q000187:drug effects / Q000378:metabolism; D015016:Yohimbine / Q000494:pharmacology*
D000927:Anticonvulsants; D015016:Yohimbine; D012701:Serotonin; D003891:Desipramine; D009638:Norepinephrine